Streetbeat News

Products Services

LEV

Synop has announced a partnership with The Lion Electric Company (NYSE:LEV) to integrate its energy management solutions with Lion's LionBeat telematics offering. The collaboration will allow Lion's electric bus and truck customers to manage their EV fleets more efficiently, with features like vehicle-to-grid technology that enables selling energy back to the grid. This partnership is expected to enhance Lion's Ecosystem portfolio and further the adoption of commercial EVs.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:08 pm

JNJ

Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIA Hemostatic Sealing Patch, designed to stop bleeding in surgeries. ETHIZIA is unique for being equally active on both sides and has shown to stop bleeding six times faster than the leading Fibrin Sealant Patch in clinical trials. It will launch in EMEA in Q1 2024, with plans for North America, APAC, and LATAM. Ethicon acquired GATT Technologies B.V. in May 2022, enhancing its portfolio with synthetic polymer technology for surgical bleeding and leak challenges.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:07 pm

WISH

ContextLogic Inc. (Wish) has launched WishPost Smart Parcel, a Logistics as a Service product aimed at providing efficient shipping solutions for non-Wish merchants. The service leverages Wish's global logistics network, offering end-to-end delivery for small parcels. Initially, it will support shipments from China to several key destinations, including the US and various European and Asian countries. This follows Wish's introduction of flat rate shipping earlier in the year.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:06 pm

SCLX

Scilex Holding Company has announced the issuance of a new U.S. patent for its lead product ZTlido, a lidocaine-containing patch for pain relief. The patent strengthens Scilex's IP position and is expected to provide barriers against competitors and support long-term growth.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:04 pm

APEI

American Public University System (APUS) has announced a new partnership with LifeRamp, a career coaching service. This collaboration aims to provide APUS students with access to transformational career coaching, enhancing their career readiness and potential job prospects.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:04 pm

TLRY

Tilray Brands, Inc. has expanded its cannabis beverage portfolio with new products from its XMG and Mollo brands, featuring THC, CBG, and CBD. The new offerings include a variety of flavors and cannabinoid profiles, with XMG introducing four new drinks and Mollo launching three. Tilray's President of Canada, Blair MacNeil, highlighted the company's leadership in the cannabis beverage market and its commitment to innovation. Tilray's stock (NASDAQ:TLRY) saw a pre-market increase of 1.73% to $1.76 per share.

Portfolio Pulse from Nina Zdinjak

November 15, 2023 | 2:04 pm

PBPB

Potbelly Corporation has entered into a 22-shop agreement in the Seattle-Tacoma region, which includes the transfer of ownership for 9 existing restaurants and the development of 13 new units in King, Pierce, and Thurston counties. This expansion is part of Potbelly's franchising strategy to grow its presence in the region.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:04 pm

AMD

AMD (NASDAQ:AMD) has announced an event titled 'Advancing AI' to launch its next-generation AMD Instinct MI300 data center GPU accelerator family. The event, scheduled for December 6, 2023, will feature AMD Chair and CEO Dr. Lisa Su, along with other executives, partners, and customers discussing AMD's impact on AI and high-performance computing. The event will be available in-person and via live stream.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:04 pm

INMB

INmune Bio Inc. (NASDAQ:INMB) has expanded its Phase II clinical trial for Alzheimer's Disease to Europe and received a $2.8M cash refund from an Australian R&D tax incentive. The trial, which is already enrolling patients in Australia, Canada, and the UK, has shown promising results in a prior Phase I trial with decreases in neuroinflammation and improvements in brain structure. The EU expansion is part of a strategy to prepare for a global Phase III trial. The Australian tax refund will be reinvested into the company's clinical programs.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:02 pm